NCT06455371 Patient-centered Dosage of Levothyroxine
| NCT ID | NCT06455371 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of North Norway |
| Condition | Hypothyroidism |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2024-12-20 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2024-12-20 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.
Eligibility Criteria
Inclusion Criteria: * Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals Exclusion Criteria: * Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06455371 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hypothyroidism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06455371 currently recruiting?
Yes, NCT06455371 is actively recruiting participants. Contact the research team at vegard.heimly.brun@unn.no for enrollment information.
Where is the NCT06455371 trial being conducted?
This trial is being conducted at Bergen, Norway, Oslo, Norway, Tromsø, Norway.
Who is sponsoring the NCT06455371 clinical trial?
NCT06455371 is sponsored by University Hospital of North Norway. The trial plans to enroll 240 participants.